肌铁蛋白:局部晚期直肠癌放疗反应与生存的潜在标志物
研究通过111例患者组织芯片免疫组化验证肌铁蛋白与局部晚期直肠癌新辅助长程放化疗反应的关系,发现低表达与良好反应相关,高表达与局部淋巴结转移和较差5年生存相关(P=0.01;HR=3.5;95%CI 1.27-10.04),体外实验显示调控肌铁蛋白可增加放射敏感性。
要点
- 低肌铁蛋白表达与局部晚期直肠癌新辅助长程放化疗良好反应相关。
- 高肌铁蛋白表达与局部淋巴结转移及较差5年生存相关(P=0.01;HR=3.5;95%CI 1.27-10.04)。
- 体外调控肌铁蛋白可增加直肠癌细胞放射敏感性,提示其作为治疗靶点的潜力。
核心结论
- 证实直肠癌中肌铁蛋白高表达与新辅助治疗反应差及长期生存较差相关。
- 体外调控肌铁蛋白可增加放射敏感性,提示肌铁蛋白或可作为靶点增强直肠癌患者对放疗的敏感性,需进一步研究。
研究设计与样本
- 对111例患者组织芯片进行免疫组化分析以验证既往蛋白质组学发现。
- 使用小干扰RNA、小分子抑制剂wj460和CRISPR-Cas9敲除细胞系调控肌铁蛋白。
- 采用二维克隆形成实验、三维球体模型和患者来源类器官评估放射增敏。
- 通过电泳、免疫荧光和免疫印迹研究潜在机制。
主要发现
- 诊断活检和肿瘤切除样本分析均证实低肌铁蛋白表达与新辅助长程放化疗良好反应相关。
- 高肌铁蛋白表达与局部淋巴结转移和较差的5年生存相关(P=0.01;风险比3.5;95%CI 1.27-10.04)。
- 该结果在Stratification in Colorectal Cancer数据库中得到外部验证。
- 永生化结直肠癌细胞系和类器官免疫印迹定量显示高肌铁蛋白表达与放射抵抗增加相关。
- 生物学和药理学调控肌铁蛋白后,所有细胞系在二维和三维模型中放射敏感性均显著增加。
关键数值与推荐
- 高肌铁蛋白表达与较差5年生存相关(P=0.01;风险比3.5;95%CI 1.27-10.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locally advanced rectal cancer often require neoadjuvant chemoradiation therapy to downstage the disease, but the response is variable with no predictive biomarkers. We have previously revealed through proteomic profiling that myoferlin is associated with response to radiation therapy. The aims of this study were to further validate this finding and explore the potential for myoferlin to act as a prognostic and/or therapeutic target. METHODS AND MATERIALS: Immunohistochemical analysis of a tissue microarray (TMA) for 111 patients was used to validate the initial proteomic findings. Manipulation of myoferlin was achieved using small interfering RNA, a small molecular inhibitor (wj460), and a CRISPR-Cas9 knockout cell line. Radiosensitization after treatment was assessed using 2-dimensional clonogenic assays, 3-dimensional spheroid models, and patient-derived organoids. Underlying mechanisms were investigated using electrophoresis, immunofluorescence, and immunoblotting. RESULTS: Analysis of both the diagnostic biopsy and tumor resection samples confirmed that low myoferlin expression correlated with a good response to neoadjuvant long-course chemoradiation therapy. High myoferlin expression was associated with spread to local lymph nodes and worse 5-year survival (P = .01; hazard ratio, 3.5; 95% CI, 1.27-10.04). This was externally validated using the Stratification in Colorectal Cancer database. Quantification of myoferlin using immunoblotting in immortalized colorectal cancer cell lines and organoids demonstrated that high myoferlin expression was associated with increased radioresistance. Biological and pharmacologic manipulation of myoferlin resulted in significantly increased radiosensitivity across all cell lines in 2-dimensional and 3-dimensional models. After irradiation, myoferlin knockdown cells had a significantly impaired ability to repair DNA double-strand breaks. This appeared to be mediated via nonhomologous end-joining. CONCLUSIONS: We have confirmed that high expression of myoferlin in rectal cancer is associated with poor response to neoadjuvant therapy and worse long-term survival. Furthermore, the manipulation of myoferlin led to increased radiosensitivity in vitro. This suggests that myoferlin could be targeted to enhance the sensitivity of patients with rectal cancer to radiation therapy, and further work is required.
引用
- Fowler H, Clifford RE, Bowden D, et al. Myoferlin: A Potential Marker of Response to Radiation Therapy and Survival in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38866213. doi:10.1016/j.ijrobp.2024.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。